Amino Acid Transport Disorder, Esophageal Cancer
Conditions
Keywords
esophageal cancer, SLC1A5
Brief summary
To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.
Detailed description
This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer. The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.
Interventions
OTHERSLC1A5 expression
To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
Sponsors
Liuzhou Maternity and Child Healthcare Hospital
Fourth Affiliated Hospital of Guangxi Medical University
Study design
Observational model
CASE_ONLY
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically proven esophageal cancer; 2. Age ≥18 years; 3. All patients must sign consent forms voluntarily;
Exclusion criteria
1. Inability to obtain histologic proof of malignancy. 2. Age \<18 years;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| optical density (ODs) of each slice by immunohistochemistry assay | within one year (plus or minus 1 month) after surgery | For immunohistochemistry assay： Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SLC1A5 expression detected by WesternBlot | within one year (plus or minus 1 month) after surgery | Western blot assay will be done by comparing the intensity of bands. To start with, xray film will be scanned on a flat-bed scanner. Then the grayscale image will be analyzed with software. Finally the Gray Value of each band will be obtained for analysis. |
Countries
China
Contacts
Primary ContactShengming Dai, Dr.
Backup ContactZheng Peng
Outcome results
None listed